Avalon Globocare CORP. 8-K Filing
Ticker: ALBT · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1630212
Sentiment: neutral
Filing Stats: 704 words · 3 min read · ~2 pages · Grade level 13.9 · Accepted 2025-11-21 16:30:51
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALBT The Nasdaq Capital M
- $3,891,270 — the Company's stockholders' equity of ($3,891,270), as reported in the Company's Quarterl
- $2,500,000 — 2025, was below the required minimum of $2,500,000, and because, as of May 22, 2025, the C
- $35 million — he market value of listed securities of $35 million or net income from continuing operation
- $500,000 — et income from continuing operations of $500,000 in the most recently completed fiscal y
Filing Documents
- ea026676901-8k_avalon.htm (8-K) — 25KB
- 0001213900-25-113638.txt ( ) — 187KB
- albt-20251119.xsd (EX-101.SCH) — 3KB
- albt-20251119_lab.xml (EX-101.LAB) — 33KB
- albt-20251119_pre.xml (EX-101.PRE) — 22KB
- ea026676901-8k_avalon_htm.xml (XML) — 4KB
01 Notice of Delisting or Failure to
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on May 22, 2025, Avalon GloboCare Corp. (the "Company") received a letter (the "May Nasdaq Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company's stockholders' equity of ($3,891,270), as reported in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025, was below the required minimum of $2,500,000, and because, as of May 22, 2025, the Company did not meet the alternative compliance standards, relating to the market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. The May Nasdaq Letter had no immediate impact on the listing of the Company's common stock, which continued to be listed and traded on The Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. Following the Company's submission of a plan to regain compliance with Listing Rule 5550(b)(1), Nasdaq granted the Company an extension of up to 180 calendar days from May 22, 2025, or through November 18, 2025, to regain compliance. On November 19, 2025, the Company received a letter (the "November Nasdaq Letter") from Nasdaq indicating that the Company was not in compliance with Listing Rule 5550(b). Unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the "Panel"), trading of the Company's common stock would be subject to suspension/delisting. Accordingly, the Company plans to timely request a hearing before the Panel, which request will automatically stay any suspension or delisting
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALON GLOBOCARE CORP. Dated: November 21, 2025 By: /s/ Luisa Ingargiola Name: Luisa Ingargiola Title: Chief Financial Officer